CHATEAU Registry: Real-world outcomes after TAVR
Official title: Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement: The Collaborative Hexagon-Asian Transcatheter Aortic Valve Replacement Union (CHATEAU) Registry
Run by Eunpyeong St. Mary's Hospital · NCT07709858 · Data updated 2026-11-12
This registry collects real-world data from adults who had TAVR between 2021 and 2025 to see how they do over time and how valve performance holds up.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 4000 (estimated) |
| Sponsor | Eunpyeong St. Mary's Hospital Academic / other |
| Locations | 1 site (Seoul) |
| Status | Recruiting |
| Started | January 1, 2021 |
| Main results expected | December 31, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | July 17, 2026 |
| Trial ID | NCT07709858 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18 years or older who underwent TAVR for severe native aortic valve disease at participating centers between 2021 and 2025 with available baseline and follow-up data.
✕Probably not a fit
Patients with missing or incomplete data may not contribute to all outcomes analyzed in the registry.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The CHATEAU Registry is a multicenter, international, observational effort using existing medical records to analyze outcomes after transcatheter aortic valve replacement. It retrospectively analyzes about 4,000 consecutive patients treated from January 1, 2021 through December 31, 2025, with follow-up through December 31, 2027. Data include demographics, comorbidities, imaging, procedural details, device information, post-procedural echocardiography, and clinical outcomes. The study aims to identify associations between patient-, anatomy-, device-, and procedure-related factors and outcomes such as death, stroke, heart failure hospitalization, pacemaker implantation, and valve performance. No new interventions or visits are performed; treatment decisions reflect routine clinical practice at participating centers.
Why it matters
Potential benefit: If successful, the registry could improve understanding of real-world TAVR outcomes and inform best practices for patient selection and device choice.
How similar studies have gone: Real-world TAVR registries have previously demonstrated important insights into safety and effectiveness, supporting the value of this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults (≥18 years of age). * Patients who underwent transcatheter aortic valve replacement (TAVR) for severe native aortic valve disease at participating centers. * TAVR performed between January 1, 2021 and December 31, 2025. * Availability of baseline procedural and follow-up clinical data in the institutional registry or medical records. Exclusion Criteria: * Patients with insufficient clinical or procedural data for outcome assessment.
Where it's running
-
The Catholic University of Korea, Eunpyeong St. Mary's Hospital
Seoul, South Korea Recruiting
Study contacts
- Principal investigator: Osung Kwon, MD, PhD — The Catholic University of Korea Eunpyeong St. Mary's Hospital
- Study coordinator: Osung Kwon, MD. PhD
- Email: oscaesar@gmail.com
- Phone: +821037085673
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
How the type of sedation affects recovery after TAVR
This study will test whether three common sedation approaches (propofol, dexmedetomidine, or midazolam with fentanyl) change how people recover on the first day after transfemoral TAVR.
-
Using 4D Flow MRI to characterize left ventricular failure
This project will test whether automated 4D Flow MRI analysis can measure left ventricular dysfunction in adults with severe aortic stenosis who are scheduled for TAVR.
-
Tracking progression and consequences of heart valve disease
This project will follow adults with moderate or worse valve disease to see if clinical tests and imaging can predict when their condition will get worse.
-
Using Ticagrelor or Aspirin for Patients After Aortic Valve Implantation
This study tests whether Ticagrelor works better than Aspirin to prevent blood clots and complications in adults with severe aortic stenosis after they have a heart valve replacement.
-
Transcatheter Aortic Valve Replacement Registry for Outcomes and Quality Monitoring
This registry collects information from hospitals about patients undergoing TAVR to see how care and outcomes compare to guidelines and nationwide data.
-
Vericiguat to slow calcific aortic valve narrowing
This trial tests whether vericiguat can slow the progression of mild-to-moderate calcific aortic valve stenosis compared with placebo.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.